JP2008540563A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540563A5
JP2008540563A5 JP2008511366A JP2008511366A JP2008540563A5 JP 2008540563 A5 JP2008540563 A5 JP 2008540563A5 JP 2008511366 A JP2008511366 A JP 2008511366A JP 2008511366 A JP2008511366 A JP 2008511366A JP 2008540563 A5 JP2008540563 A5 JP 2008540563A5
Authority
JP
Japan
Prior art keywords
antibody
composition
nebulizer
mutated
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008511366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540563A (ja
Filing date
Publication date
Priority claimed from US11/127,438 external-priority patent/US20050271660A1/en
Application filed filed Critical
Publication of JP2008540563A publication Critical patent/JP2008540563A/ja
Publication of JP2008540563A5 publication Critical patent/JP2008540563A5/ja
Withdrawn legal-status Critical Current

Links

JP2008511366A 2005-05-11 2006-05-10 肺疾患を処置するためのモノクローナル抗体の霧状化 Withdrawn JP2008540563A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/127,438 US20050271660A1 (en) 2002-09-06 2005-05-11 Nebulization of monoclonal antibodies for treating pulmonary diseases
PCT/US2006/018269 WO2006122257A2 (en) 2005-05-11 2006-05-10 Nebulization of monoclonal antibodies for treating pulmonary diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012193985A Division JP2012233013A (ja) 2005-05-11 2012-09-04 肺疾患を処置するためのモノクローナル抗体の霧状化

Publications (2)

Publication Number Publication Date
JP2008540563A JP2008540563A (ja) 2008-11-20
JP2008540563A5 true JP2008540563A5 (https=) 2009-06-04

Family

ID=37054603

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008511366A Withdrawn JP2008540563A (ja) 2005-05-11 2006-05-10 肺疾患を処置するためのモノクローナル抗体の霧状化
JP2012193985A Pending JP2012233013A (ja) 2005-05-11 2012-09-04 肺疾患を処置するためのモノクローナル抗体の霧状化
JP2014125985A Pending JP2014169332A (ja) 2005-05-11 2014-06-19 肺疾患を処置するためのモノクローナル抗体の霧状化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012193985A Pending JP2012233013A (ja) 2005-05-11 2012-09-04 肺疾患を処置するためのモノクローナル抗体の霧状化
JP2014125985A Pending JP2014169332A (ja) 2005-05-11 2014-06-19 肺疾患を処置するためのモノクローナル抗体の霧状化

Country Status (7)

Country Link
US (5) US20050271660A1 (https=)
EP (1) EP1881993A2 (https=)
JP (3) JP2008540563A (https=)
AU (1) AU2006243994B2 (https=)
CA (1) CA2608195A1 (https=)
NZ (2) NZ563509A (https=)
WO (1) WO2006122257A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体成分c5に対する抗体を使用する喘息の処置の方法
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2005048982A2 (en) * 2003-11-17 2005-06-02 Nektar Therapeutics Efficient introduction of an aerosol into a ventilator circuit
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20070191262A1 (en) * 2005-11-15 2007-08-16 University Of Iowa Research Foundation Cancer Therapy and Prevention Based on Modulation of Complement activity
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
US8312879B2 (en) * 2006-10-16 2012-11-20 General Electric Company Method and apparatus for airway compensation control
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
HRP20150279T1 (hr) * 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
AU2009215846B2 (en) * 2008-02-19 2014-08-14 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
US20220281964A1 (en) * 2008-02-25 2022-09-08 Xencor, Inc. Fc VARIANTS WITH ALTERED BINDING TO FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
PT2387583T (pt) * 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2427497B1 (fr) * 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
DK2533761T3 (da) 2010-02-11 2019-06-24 Ablynx Nv Fremgangsmåder og sammensætninger til fremstilling af aerosoler
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
WO2012030645A1 (en) * 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
TW201400499A (zh) * 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
EP2879697A4 (en) 2012-08-03 2016-01-20 Lfb Usa Inc USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
EP2978451B1 (en) 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3125942B8 (en) 2014-04-03 2021-12-01 CSL Behring AG Nebulization of immunoglobulin
JP6532034B2 (ja) * 2015-03-24 2019-06-19 学校法人関西医科大学 鼻腔抵抗の測定方法、鼻腔抵抗及び肺気道抵抗の測定方法及び該方法の実施に用いる測定装置
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
DK3658184T5 (da) 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
EP3873602B1 (en) 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
KR20230005268A (ko) 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
WO2022215054A1 (en) 2021-04-09 2022-10-13 Takeda Pharmaceutical Company Limited Antibodies targeting complement factor d and uses therof
CA3216770A1 (en) 2021-04-26 2022-11-03 Tomoki Yoshihara Anti-clec12a antibodies and uses thereof
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
IL311837A (en) 2021-10-20 2024-05-01 Takeda Pharmaceuticals Co Compositions targeting bcma and methods of use thereof
JP2025508050A (ja) * 2022-03-07 2025-03-21 ンカルタ・インコーポレイテッド Cd70指向性がん免疫療法のための多重遺伝子編集細胞
EP4507720A1 (en) 2022-04-14 2025-02-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
CN117100857B (zh) * 2023-08-15 2024-09-10 福建医科大学附属协和医院 一种抗体金纳米笼载药系统、制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228795A (en) * 1977-03-08 1980-10-21 Babington Robert S Apparatus for producing finely divided liquid spray
EP0530216A4 (en) * 1990-04-19 1993-06-30 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
WO1992001473A1 (en) * 1990-07-19 1992-02-06 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
DE69328098T2 (de) 1992-06-24 2000-08-24 Adprotech Plc, Royston Lösliche derivate des complement type-rezeptors (cr1)
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US20010036650A1 (en) * 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
DE69534701T2 (de) 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
JP2002511837A (ja) * 1996-09-10 2002-04-16 メデイノックス,インコーポレイテッド ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用
EP0934341A1 (en) 1996-10-28 1999-08-11 Farmac Nederland B.V. Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US20020182260A1 (en) * 1998-05-29 2002-12-05 Cellegy Pharmaceuticals, Inc. Anti-inflammatory agents and methods for their preparation and use
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
CA2362338A1 (en) * 1998-07-30 2000-02-10 Human Rt. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7109299B1 (en) * 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6998468B2 (en) * 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1349874A2 (en) * 2000-06-21 2003-10-08 ZymoGenetics, Inc. Peptide and polypeptide inhibitors of complement c1s
KR100919593B1 (ko) * 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
WO2002076196A1 (en) * 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP2005526769A (ja) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療剤を全身搬送するための中央気道投与
CA2480082A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体成分c5に対する抗体を使用する喘息の処置の方法
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20030124139A1 (en) * 2002-11-20 2003-07-03 Irina Esikova Compositions and methods for stabilizing biological molecules upon lyophilization
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
CA2674608A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
JP4538514B2 (ja) 2008-07-30 2010-09-08 シャープ株式会社 画像圧縮方法、画像圧縮装置、画像形成装置、コンピュータプログラム及び記録媒体
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies

Similar Documents

Publication Publication Date Title
JP2008540563A5 (https=)
Newman Principles of metered-dose inhaler design
JP2012528200A5 (https=)
JP2012528792A5 (https=)
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
JP2007520508A5 (https=)
RU2017144619A (ru) Катионы одновалентных металлов сухих порошков для ингаляций
HRP20220919T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća
JP5800829B2 (ja) Copd用エアロゾル製剤
JP2007522229A5 (https=)
JP2019517597A5 (https=)
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
JP2014510064A5 (https=)
HRP20050570A2 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmetrol xinafoate
CN111936124A (zh) 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN102186458A (zh) 治疗慢性阻塞性肺病及其它肺疾病的方法
JP2005532988A5 (https=)
JP2007528409A5 (https=)
JP2007527430A5 (https=)
CA2558426A1 (en) Formulations decreasing particle exhalation
JP2020023536A (ja) Copdの治療のためのフォルモテロール及びブデソニドの組み合わせ
CN115768402A (zh) 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮
KR20220137051A (ko) 염증성 폐질환의 흡입치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
US20130125882A1 (en) Method and composition for treating asthma and copd
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata